Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2022
Insurer to return $40 million in health care claims to 600,000 Aussies
20 September 2022 - Health insurance company nib is returning $40 million in health care claims to more than 600,000 ...
Posted by Michael Wonder on 20 Sep 2022
NICE recommends BeiGene’s Brukinsa (zanubrutinib) for patients with Waldenström’s macroglobulinaemia who have had at least one treatment
19 September 2022 - Brukinsa Is the first Bruton’s tyrosine kinase inhibitor recommended by NICE for routine use for Waldenström’s macroglobulinaemia. ...
Posted by Michael Wonder on 19 Sep 2022
Registry-based randomised trials: the best of both worlds?
15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...
Posted by Michael Wonder on 19 Sep 2022
PHARMAC considering multiple new treatments from Takeda
19 September 2022 - Pharmac has initiated consultation today on a provisional bundle deal with Takeda to fund vedolizumab for people ...
Posted by Michael Wonder on 16 Sep 2022
PHARMAC can't progress cystic fibrosis drug Trikafta - CF New Zealand
16 September 2022 - PHARMAC is not in a position to progress funding on the life-extending cystic fibrosis drug, Trikafta, ...
Posted by Michael Wonder on 15 Sep 2022
Can the proposed listing of two medicines from the same supplier really be called a bundle deal?
16 September 2022 - On Wednesday, PHARMAC announced a "medicines bundle to provide more treatment options for New Zealanders." ...
Posted by Michael Wonder on 15 Sep 2022
Advicenne updates on availability of Sibnayal to patients and caregivers in Great Britain
14 September 2022 - Sibnayal has been accepted for use within NHS Scotland. ...
Posted by Michael Wonder on 15 Sep 2022
Advocates welcome PHARMAC's removal of barriers to menopausal symptoms treatment
15 September 2022 - A women's health expert says today marks a major win for wāhine in Aotearoa, with PHARMAC ...
Posted by Michael Wonder on 15 Sep 2022
Progesterone to be fully funded for all who need it
15 September 2022 - PHARMAC has today confirmed that it is removing all funding restrictions from progesterone, with tens of thousands ...
Posted by Michael Wonder on 14 Sep 2022
Dexamethasone intravitreal implant for treating diabetic macular oedema
14 September 2022 - NICE has published evidence-based recommendations on the use of dexamethasone intravitreal implant for the treatment of ...
Posted by Michael Wonder on 14 Sep 2022
Has there actually been early resolution for early resolution resubmissions?
15 September 2022 - Following on from this week's article on early re-entry resubmissions, today we took a close look ...
Posted by Michael Wonder on 14 Sep 2022
Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex
14 September 2022 - Therapy is for the treatment of spasticity due to multiple sclerosis. ...
Posted by Michael Wonder on 14 Sep 2022
NICE inks another early full stop on the appraisal of a cancer medicine
14 September 2022 - Once again, the sponsor decided not to provide an evidence submission. ...
Posted by Michael Wonder on 14 Sep 2022
PHARMAC announces medicines bundle to provide more treatment options for New Zealanders
14 September 2022 - PHARMAC is considering funding two medicines as part of a new bundle agreement that would offer ...
Posted by Michael Wonder on 13 Sep 2022
CADTH partners with international health technology assessment bodies to boost collaboration on shared challenges
6 September 2022 - Six health technology assessment bodies from three continents will join forces to collaborate on a range of ...